Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Efatutazone, an oral PPAR-╬│ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.

PMID:
23589525
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD.

Cancer. 2012 Nov 1;118(21):5403-13. doi: 10.1002/cncr.27526. Epub 2012 May 8.

PMID:
22570147
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.

Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.

Cancer. 2004 Nov 1;101(9):2034-41.

PMID:
15455357
[PubMed - indexed for MEDLINE]
Free Article
4.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG.

J Clin Oncol. 2009 Sep 10;27(26):4413-21. doi: 10.1200/JCO.2008.21.7422. Epub 2009 Aug 3.

PMID:
19652058
[PubMed - indexed for MEDLINE]
5.

A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.

Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. doi: 10.1007/s00280-008-0693-y. Epub 2008 Mar 4.

PMID:
18317763
[PubMed - indexed for MEDLINE]
6.

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.

Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK.

Clin Cancer Res. 2004 May 1;10(9):2968-76.

PMID:
15131032
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.

Schwartzberg LS, Arena FP, Mintzer DM, Epperson AL, Walker MS.

Clin Breast Cancer. 2012 Apr;12(2):87-93. doi: 10.1016/j.clbc.2011.10.004. Epub 2011 Dec 6.

PMID:
22154117
[PubMed - indexed for MEDLINE]
8.

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.

Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, Vo Van ML, Bondarenko I.

Br J Cancer. 2013 May 28;108(10):1985-93. doi: 10.1038/bjc.2013.178. Epub 2013 Apr 30.

PMID:
23632474
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, Hyodo I, Yachi Y, Onuma H, Ohtsu A.

Invest New Drugs. 2014 Jun;32(3):473-80. doi: 10.1007/s10637-013-0056-3. Epub 2013 Dec 15.

PMID:
24337768
[PubMed - in process]
Free PMC Article
10.

Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.

Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC.

Oncogene. 2006 Apr 13;25(16):2304-17.

PMID:
16331265
[PubMed - indexed for MEDLINE]
11.

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.

Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA.

Clin Breast Cancer. 2007 Feb;7(6):465-70.

PMID:
17386123
[PubMed - indexed for MEDLINE]
12.

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.

D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.

Clin Cancer Res. 1999 Feb;5(2):275-9.

PMID:
10037175
[PubMed - indexed for MEDLINE]
Free Article
13.

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

Calabr├▓ F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN.

Cancer. 2009 Jun 15;115(12):2652-9. doi: 10.1002/cncr.24313.

PMID:
19396817
[PubMed - indexed for MEDLINE]
Free Article
14.

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ.

Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123.

PMID:
18676756
[PubMed - indexed for MEDLINE]
Free Article
15.

A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.

Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA Jr.

Clin Cancer Res. 1997 Jul;3(7):1117-23.

PMID:
9815791
[PubMed - indexed for MEDLINE]
Free Article
16.

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.

du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt VL, Harter P.

Ann Oncol. 2010 Feb;21(2):370-5. doi: 10.1093/annonc/mdp506. Epub 2009 Nov 4.

PMID:
19889612
[PubMed - indexed for MEDLINE]
Free Article
17.

A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.

Clin Cancer Res. 2003 Sep 15;9(11):4108-15.

PMID:
14519633
[PubMed - indexed for MEDLINE]
Free Article
18.

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.

Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, Olson S, Nemunaitis J.

Cancer Invest. 2004;22(6):886-96.

PMID:
15641487
[PubMed - indexed for MEDLINE]
19.

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.

Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK.

J Clin Oncol. 2004 Jun 15;22(12):2321-7.

PMID:
15197193
[PubMed - indexed for MEDLINE]
20.

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.

Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC.

Thyroid. 2009 Mar;19(3):233-40. doi: 10.1089/thy.2008.0321.

PMID:
19265494
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk